Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.12 CAD
Change Today +0.01 / 9.09%
Volume 95.5K
APC On Other Exchanges
As of 2:11 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

advanced proteome therapeuti (APC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/12/14 - C$0.32
52 Week Low
03/18/15 - C$0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

advanced proteome therapeuti (APC) Related Businessweek News

No Related Businessweek News Found

advanced proteome therapeuti (APC) Details

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. It focuses on the development of a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. The company is headquartered in Boston, Massachusetts.

advanced proteome therapeuti (APC) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $175.0K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

advanced proteome therapeuti (APC) Key Developments

Advanced Proteome Therapeutics Corporation Appoints Randal Chase to its Board of Directors

Advanced Proteome Therapeutics Corporation announced the appointment of Dr. Randal Chase to its Board of Directors. Dr. Chase currently serves as Chairman of MediMabs and is a member of the Board of Geovax Labs Inc. Most recently, Dr. Chase was Chairman of the Board and Director of Medicago.

Advanced Proteome Therapeutics Corporation, Annual General Meeting, Jul 28, 2015

Advanced Proteome Therapeutics Corporation, Annual General Meeting, Jul 28, 2015., at 10:00 Pacific Standard Time. Location: English Bay Room, Computershare, 3rd Floor. Agenda: To receive the audited financial statements of the company for its financial year ended July 31, 2014 and the report of the auditors thereon; to set the number of directors of the company to be elected at four; to elect directors of the company for the ensuing year; to appoint auditors of the company for the ensuing year and to authorize the directors to fix their remuneration for the ensuing year; to ratify and approve the company's stock option plan; to consider any permitted amendment to or variation of any matter identified in this Notice and to transact such other business as may properly come before the Meeting or any adjournment thereof.

Advanced Proteome Therapeutics Announces Promising Results of Triple Combination Immunotherapy Tests

Advanced Proteome Therapeutics Corporation announced the first results of testing a triple combination of immunotherapies in animal models. These preliminary tests were carried out in conjunction with its academic collaborators. The tests compared the effects of the triple combination on tumor retardation and tumor free survival in an animal study with those of an anti-CTLA-4 antibody, a 41-BB antibody, or APC 104, separately, as well as in the various double combinations. The triple combination proved to be superior in retarding growth of tumors from implanted CMS5 tumor cells as well as increasing tumor free survival. Tumor free survival (TFS) was recorded in eight cohorts of mice over several weeks. Tumor free survival was 80% in mice treated with the triple combination (group 8) at the endpoint of the study. By contrast, during the same period, TFS varied in the other groups involving the administration of single entities and double combinations from 0% (group 2), 20% (group 3), 40% (groups 4, 5) to 60% (groups 6, 7). Untreated mice (group 1) did not survive beyond 3 weeks. These tests feature APC 104 in combination with both a checkpoint inhibitor (an anti-CTLA-4 antibody) and the co-stimulatory molecule 41-BB. The latter is known to increase the proliferation of immune cells capable of killing tumor cells and to enhance tumor rejection. APC 104 is a molecule which has been designed to increase the duration of action of APC’s protein delivery system to tumors. The recent clinical success of immunotherapies that interfere with immune checkpoint receptors has resulted in a surge of interest in immunotherapy as a mainstream form of cancer treatment. However, checkpoint inhibition alone, which releases the brakes on the immune system, although strikingly effective in specific subsets of patients, is not sufficient to promote tumor regression in a majority of patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APC:CN C$0.12 CAD +0.01

APC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APC.
View Industry Companies

Industry Analysis


Industry Average

Valuation APC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED PROTEOME THERAPEUTI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at